Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2015

View Archived Issues

Activation of engram cells by positive memories may suppress depression-related behaviors

Apceth and University of Cologne to develop cellular immunotherapies for cancer

Eligo Bioscience's development of antibiotics supported by new investment

Toulouse University Cancer Institute and Pierre Fabre sign framework agreement in oncology

Cleveland BioLabs reports data from phase I study of CBLB-612

Allegro Ophthalmics reports topline data from phase II study of Luminate

C3 Jian completes second phase II study of C16G2

Preliminary data presented on safety, PK and PD of PF-0538062 for hemophilia

FDA approves Iressa for metastatic NSCLC with certain EGFR mutations

Clozapine is a potent antiplatelet agent

Ferring to collaborate with Intralytix on bacteriophage therapy for IBD

Roche discloses V1A receptor antagonists

Cav2.2 blockers developed at Gruenenthal

Sunshine Lake Pharma reports 5-HT6 antagonists

Bayer Schering Pharma discloses EP4 antagonists

Bayer Schering Pharma presents alpha2C-adrenoceptor antagonists

RaQualia begins first-in-human study of 5-HT2B antagonist RQ-00310941

Anacor discloses positive results from phase III trials of crisaborole in atopic dermatitis

Phase III ENSPIRIT trial of custirsen sodium continues following final interim futility analysis

Blueprint Medicines receives FDA clearance to start phase I trials of BLU-554 and BLU-285

New phase I study investigates cabozantinib in combination therapy for genitourinary tumors

Results of in vivo neuroblastoma study of anisina plus vincristine

ACT-246475 shows a wider therapeutic window than ticagrelor

Researchers develop an improved p21 reporter mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...